Effects of twice daily application of 2% dorzolamide on intraocular pressure in normal cats

Veterinary Ophthalmology

Volumn 6, Issue 2, 2003, Pages 147-150

  Rainbow, Marc E ^a   Dziezyc, Joan ^b  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Carbonic anhydrase inhibitor; Cat; Dorzolamide; Glaucoma

Indexed keywords

CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; EYE DROPS; SULFONAMIDE; THIOPHENE DERIVATIVE;

ARTICLE; CAT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; INTRAOCULAR PRESSURE; MALE; NONHUMAN; TONOMETER; ANIMAL; ANIMAL DISEASE; OCULOPLETHYSMOGRAPHY; PHYSIOLOGY; REFERENCE VALUE; TOPICAL DRUG ADMINISTRATION;

FELIS CATUS;

ADMINISTRATION, TOPICAL; ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CATS; FEMALE; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; REFERENCE VALUES; SULFONAMIDES; THIOPHENES; TONOMETRY, OCULAR;

EID: 0037629986     PISSN: 14635216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-5224.2003.00282.x     Document Type: Article

References (26)

1. Mincione F, Menabuoni L, Mincione G et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IV with N-hydroxysulfonamides - a novel class of intraocular pressure lowering agents. Journal of Enzyme Inhibitors 1998, 13: 267-284.
2. Surgue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Progress in Retinal Eye Research 2000; 19: 87-112.
3. Higginbotham EJ. Topical carbonic anhydrase inhibitors. Ophthalmology Clinics of North America 1989; 2: 113-130.
4. Davidson MG. Dorzolamide. Compendium of Continuing Education for Practicing Veterinarians 2000; 22: 340-342.
5. Gwin RM. Current concepts in small animal glaucoma: recognition and treatment. Veterinary Clinics of North America: Small Animal Practice 1980; 10: 357-376.
6. Maron TH, Conroy CW, Levy NS. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. Journal of Ocular Pharmacology and Therapeutics 1997; 12: 23-30.
7. Miller PE, Pickett JP, Majors LJ, Kurzman ID. Evaluation of two applanation tonometers in cats. American Journal of Veterinary Research 1991; 52: 1917-1921.
8. Blocker T, van der Woerdt A. The feline glaucomas: 82 cases (1995-1999). Veterinary Ophthalmology 2001; 4: 81-85.
9. Szymanski CM, Latimer CA. Disease of the eye. In: The Cat: Diseases and Clinical Management, Vol. II. (ed. Sherding RG) Churchill Livingston Inc., New York, 1989; 1639-1674.
10. Glaze MB, Gelatt KN. Feline ophthalmology. In: Veterinary Ophthalmology, 3rd edn. (ed. Gelatt KN) Lippincott/Williams & Wilkins, Baltimore, 1999; 997-1052.
11. Wilcock BP, Peiffer RL, Davidson MG. The causes of glaucoma in cats. Veterinary Pathology 1990; 27: 35-40.
12. Peiffer RL. Feline ophthalmology. In: Textbook of Veterinary Ophthalmology. (ed. Gelatt KN) Lea & Febiger, Philadelphia, 1981; 521-568.
13. Brightman AH. The eye. In: Feline Medicine. (ed. Pratt P) American Veterinary Publications, Santa Barbara, 1993; 605-622.
14. Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure in cats. American Journal of Veterinary Research 1991; 52: 436-439.
15. Wilkie DA, Latimer CA. Effects of topical administration of 2.0% pilocarpine on intraocular pressure in cats. American Journal of Veterinary Research 1991; 52: 441-444.
16. Othman GM, Samy MT. Can carbonic anhydrase inhibitors relieve intraocular pressure in cats with glaucoma? Veterinary Medicine 1987; 82: 498-509.
17. Fanous MM, Challa P, Maren TH. Comparison of intraocular pressure lowering by topical and systemic carbonic anhydrase inhibitors in the rabbit. Journal of Ocular Pharmacology and Therapeutics 1999; 15: 51-57.
18. King TC, Gum GG, Gelatt KN. Evaluation of topically administered carbonic anhydrase inhibitor (MK-927) in normotensive and glaucomatous beagles. American Journal of Veterinary Research 1991; 52: 2067-2070.
19. Egorov AE. The hypotensive action and side effects of the carbonic anhydrase inhibitor dorzolamide hydrochloride. Vestnik Oftalmologii 1996; 112: 3-4.
20. Simpson AJ, Gray TB, Ballantyne C. A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study. Australian, New Zealand Journal of Ophthalmology 1996; 24: 39-42.
21. Adamsons IA, Polis A, Ostov CS, Boyle JE. Two year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide safety Study Group. Journal of Glaucoma 1998; 7: 395-401.
22. Strohmaier K, Swyder E, Dubiner H. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-timolol Study Group. Ophthalmology 1998; 105: 1936-1944.
23. Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. Journal of Ocular Pharmacology and Therapeutics 1996; 12: 363-376.
24. Lippa EA, Carlson LE, Ehinger B et al. Dose-response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Archives of Ophthalmology 1992; 110: 495-499.
25. Balfour JA, Wilde M. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997; 10: 384-403.
26. Schmitz K, Banditt P, Motschmann M et al. Population pharmokinetics of 2% topical dorzolamide in aqueous humor of humans. Investigative Ophthalmology and Visual Sciences 1999; 40: 1621-1624.